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Abstract
Background: Smooth muscle cells, present in the saphenous vein (SV) tunica media, may 
contribute to late occlusion of venous aortocoronary grafts. The aim of present study was to 
evaluate expression of selected cytoskeletal proteins in tunica media of SV grafts obtained from 
patients undergoing coronary artery bypass grafting (CABG) and correlate procured results to 
late venous graft failure observed in these patients.
Methods: The study involved 218 patients (mean age of 62.5 ± 8.7 years) who underwent 
primary isolated CABG with the use of at least one venous aortocoronary bypass graft. Expres-
sions of a-smooth muscle actin, smooth muscle-myosin heavy chain, calponin and cytokeratin 8  
in SV wall were estimated by means of immunohistochemistry. The primary clinical endpoint 
was defined as the presence of any coronary artery disease (CAD) progression symptom while 
angiographic one as significant stenosis in the venous graft.
Results: Thirty-eight (18.1%) patients have reached the primary clinical endpoint. Freedom 
from clinical CAD deterioration was 0.95 ± 0.02, 0.87 ± 0.03 and 0.83 ± 0.04, for 12-, 24-, 
36-month follow-up, respectively. Forty-four study participants have reached the angiographic 
endpoint. Multivariate logistic regression analysis revealed an increased expression of cy-
tokeratin 8 accompanied by calponin underexpression in SV tunica media were independent 
risk factors for venous graft failure.
Conclusions: An increased expression of cytokeratin 8 and weak of calponin in tunica media 
of SV grafts might be useful markers of unfavorable long-term prognosis in CABG patients. In 
the future, assessment of their expression may enable to select the most appropriate candidates 
for SV grafts. (Cardiol J 2013; 20, 6: 583–591)
Key words: coronary artery bypass grafting, saphenous vein, calponin,  
cytokeratin 8, outcome
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Introduction
Coronary artery bypass grafting (CABG) is 
a method of choice in treatment of patients with 
severe multi-vessel coronary artery disease (CAD) 
[1]. In majority of cases, it significantly improves 
the quality of life, alleviating the patient from co-
ronary symptoms [2, 3]. A long-term outcome in 
CABG patients depends, however, on graft patency 
rate as well as atherosclerotic progression in native 
coronary arteries. It is commonly accepted arterial 
grafts, particularly left internal mammary artery 
implanted to the left anterior descending artery, 
result in higher late patency rates as compared to 
the venous conduits [4]. Unfortunately, the ade-
quate arterial conduits are not always available, 
thus more easily harvested saphenous vein (SV) 
grafts are still widely used.
There are at least 3 principal mechanisms 
leading to venous graft failure. They include 
thrombosis, intimal hyperplasia and accelerated 
atherosclerosis [5]. Among others, vascular smooth 
muscle cells (SMCs) are believed to play a crucial 
role in pathogenesis of the late graft occlusion [6]. 
Secondary to locally distributed stimulating agents, 
they are able to migrate through internal elastic 
lamina to tunica intima, proliferate and secrete 
extracellular matrix [7]. It results in progressive 
neointimal formation that might lead to the decisive 
narrowing of the grafts and clinically CAD progres-
sion or angina recurrence and, in some cases, acute 
coronary syndromes (ACSs) [8]. 
On the other hand, the populations of both 
arterial and venous SMCs were reported to be 
heterogeneous and manifest at least 2 phenotypes: 
elongated/spindle-like cells or epithelioid/rhomboid 
shaped cells that expressed a variant proliferative 
and chemotactic activity [9, 10]. Subtypes of SMCs 
were also characterized by altered expression of 
smooth muscle proteins such as smooth muscle 
myosin heavy chain (SM-MHC), calponin (CALP) 
and cytokeratin 8 (CK8) that were associated with 
various stages of cellular differentiation [10]. SM-
-MHC and CALP are expressed predominantly in 
the mature SMCs while CK8 expression is typical 
for fetal and poorly differentiated cells [10–12].
In line with the above, the aim of the present 
study was to evaluate expression of selected cy-
toskeletal proteins in tunica media of SV grafts 
obtained from CABG patients and correlate pro-




Local Ethics Committee has approved a re-
search protocol (No.1201/08) and an informed 
written consent from each study participant was 
obtained. In total, 218 consecutive patients (168 
[77.1%] males and 50 [22.9%] females) at the 
mean age of 62.5 ± 8.7 years (46–85 years) who 
underwent primary isolated CABG with the use 
of at least one venous aortocoronary bypass graft 
between August 2008 and February 2009 were 
enrolled in the prospective study. Patients who 
needed emergent operations and with any periph-
eral veins pathologies were excluded from the 
study. Basic preoperative demographics and clinical 
history data are summarized in Table 1.
Operation procedure and sample collection
All surgeries were performed from median 
sternotomy. A part of them were accomplished on 
the beating heart (off-pump coronary artery bypass, 
Table 1. Pre- and intraoperative clinical data
Parameters Patients  
(n = 218)
Age 62.5 ± 8.7
Gender (male/female) 168/50
Body mass index (BMI) 29.3 ± 4.1
Obesity (BMI > 30) 92 (42.2%)
Coronary artery disease:
Stable angina 180 (82.6%)
Unstable angina 38 (17.4%)
History of infarct 140 (64.2%)
Previous PCI 66 (30.3%)
Arterial hypertension 162 (74.3%)
Diabetes mellitus 98 (45.4)
Hyperlipidemia 92 (42.4%)
Peripheral vascular disease 50 (22.9%)
Neurological events 18 (8.3%)
CCABG/OPCAB 130/88
Number of grafts/patient 2.6 ± 0.6
Grafts type (distal anastomoses):
Arterial (LIMA, RIMA, RA) 235
Venous 349
Complete revascularization* 154 (70.6%)
*Means all severely stenotic or occluded native coronary  
arteries were bypassed; CCABG — conventional coronary  
artery bypass (in the extracorporeal circulation); LIMA — left 
internal mammary artery; OPCAB — off-pump coronary artery 
bypass; PCI — percutaneous coronary intervention; RA — radial 
artery; RIMA — right internal mammary artery
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OPCAB) with the routine use of tissue stabilizer 
(Octopus 4) and intracoronary shunts (ClearView) 
(both, Medtronic Inc., USA). The others were 
carried out in the extracorporeal circulation in 
the moderate hypothermia (conventional CABG) 
(Table 1).
SV was obtained through a full-length thigh 
incision over its course [13]. Key points included 
minimal manipulation of the graft (“no-touch” tech-
nique), avoiding of extensive dilation of the condu-
its, using low-intensity electrocautery and control 
of the branches with stainless-steel vascular clips. 
In all the cases, the distal part of harvested SV 
segment (at least 1.5–2.0 cm in length) was saved 
for subsequent laboratory studies.
Immunohistochemistry
The venous segments were carefully rinsed 
with 0.9% NaCl at the room temperature, slightly 
dilated and fixed in Bouin’s solution for 2–3 h. 
They were dehydrated and then embedded in 
paraffin blocks by means of routine procedure. 
Eventually, they were cut into 5-mm sections on 
a semi-automatic rotary microtome (Leica RM 2145, 
Leica Microsystems, Nussloch, Germany). Each 
sample of the SV (taken from separate patients) 
was cut into approximately 30 paraffin sections. All 
of the immunohistochemical (ICC) analyses em-
ployed StreptABComplex/HRP method modified 
by use of biotinylated tyramide (Dako Catalyzed 
Signal Amplification System, Peroxidase, K1500, 
DakoCytomation A/S, Glostrup, Denmark) as 
previously described [14]. After deparaffinization 
with xylene and gradual rehydratation the endo-
genous peroxidase activity was blocked with 10% 
hydrogen peroxide (v/v) treatment for 10 min. At 
the consecutive stages of ICC, the indirect ABC 
technique was performed, with the following steps: 
(1) preincubation with the appropriate normal 
goat serum in phosphate buffered solution for 
30 min at room temperature; (2) incubation with 
the first specific antibody, overnight at 4°C in 
a hybridization chamber; (3) incubation with the 
secondary antibody for 60 min at room tempera-
ture; (4) final antigen-antibody complexes staining 
using 0.5% 3-3’ diaminobenzidine (DAB; Sigma 
Chemical Co., St. Louis, MO).
The following monoclonal mouse anti-human 
specific antibodies were used: anti-a-smooth 
muscle actin (a-SM actin) (M0851), anti-SM-MHC 
(MAB13431), anti-CALP (M3556) (all from Dako-
Cytomation A/S, Glostrup, Denmark) and anti-CK8 
(ab9023; Abcam, Cambrigde, UK).
The intensity of cytoplasmic protein expres-
sion was assessed using the semi-quantitative im-
muno-reactive score (IRS) scale according to Rem-
mele and Stenger [15]. It takes into account the 
percentage of positive cells (scale from 0 to 4) and 
the intensity of the color reaction (scale from 0 to 3) 
and final score that ranges from 0 to 12 is a pro-
duct of points given for individual traits (Table 2). 
On the base of IRS, cytoplasmic protein expression 
was defined as negative (IRS 0–1), positive weak 
(IRS 2–3), positive moderate (IRS 4–6) or strong 
(IRS 7–12) [16]. All tissue sections were analyzed 
under AxioImager Z.1 light microscope and selec-
ted pictures were captured with attached AxioCam 
MRc5 digital camera (Carl Zeiss MicroImaging 
GmbH, Göttingen, Germany).
ICC analysis of proteins expression in each 
vessel section was done within 10 representative 
microscopic fields (× 200 magnification). Intensity 
of ICC reaction was evaluated independently by 
2 pathologists on coded samples. Additionally, all 
of ICC analyses included the negative controls 
that consisted of specimens incubated with non-
immune IgG1 (X-0931, DakoCytomation A/S, 
Glostrup, Denmark) and sections in which the 
primary or secondary antibody was omitted. 
Evaluation of late coronary outcome
The primary clinical endpoint of this prospecti-
ve study included any clinical form of CAD progres-
sion that occurred throughout post-discharge fol-
low-up. It confines all ACSs cases (unstable angina, 
myocardial infarction (MI) with or without ST seg-
Table 2. Immunohistochemical analysis of cytoskeletal expression using Remmele scale [15]
Percentage of positive cells Points Intensity of color reaction Points
No positive cells 0 No reaction 0
< 10% positive cells 1 Weak color reaction 1
10–50% positive cells 2 Moderate color reaction 2
51–80% positive cells 3 Strong color reaction 3
> 80% positive cells 4
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ment elevation, respectively STEMI or NSTEMI) 
as well as recurrence or progression of stable an-
gina according to Canadian Cardiovascular Society 
(CCS) classification. Patients CCS status was as-
sessed at the end of postoperative rehabilitation 
(usually 4 weeks after surgery) and then at the 
end of follow-up. Additionally, at the end of follow-
-up, all aortocoronary bypass grafts were exami-
ned by means of coronary angiography (n = 187) 
or computed tomography angiography (CTA) with 
multi-slice detector (n = 23). CTA was offered only to 
subject who withdrew consent for follow-up invasive 
coronary examination. Hemodynamically significant 
SV disease was defined as graft lumen restriction 
exceeded 70% (the primary angiographic endpoint).
Clinical data and SMCs protein expression in  
patients with lesions in venous bypass grafts
Selected preoperative clinical and intraoperati-
ve data were compared between groups of patients 
with and without significant venous graft disease in 
the last follow-up coronary angiography: SVGD(+) 
vs. SVDG(–), respectively. Moreover, expression 
of SMCs proteins such as SM-MHC, CALP and 
CK8 in SV segments obtained from patients of 
both subgroups was also recalculated and analyzed.
Data management and statistical analysis
Initially, all continuous variables were esti-
mated for normality with the Shapiro-Wilk W test. 
When they complied with a normal distribution 
they were expressed as the mean ± standard 
deviation and then they were compared using un-
-paired t test. Non-parametric continuous variables 
expressed as median (25th–75th percentile) were 
compared using Mann-Whitney U test. Categorical 
data were expressed as number (n) and percent (%) 
or median (25th–75th percentile) and were compared 
employing Pearson c2 test or Kruskal-Wallis test. 
A p value < 0.05 was considered to be as statisti-
cally significant.
The univariate followed by multivariate logis-
tic regression analysis of the several variables (de-
mographic, clinical, immunohistochemical) were 
performed to identify predictors for accelerated 
venous graft disease development (angiographic 
endpoint of the study). Only variables with a p value 
of < 0.2 by means of univariate regression model 
were entered into a multivariate logistic regression 
one. Variables revealed to be significant (p < 0.05) 
at the latter model were considered to be indepen-
dent predictors for accelerated graft failure. The 
p values and odds ratios (ORs) with corresponding 
95% confidence intervals (95% CI) were presented. 
The following variables, including risk factors of athe-
rosclerosis development (advanced age [> 70 years], 
gender, obesity [BMI > 30], preoperative unstable 
angina, previous MI and previous percutaneous 
coronary intervention [PCI], arterial hypertension, 
diabetes mellitus treated with insulin, hyperlipid-
emia, peripheral vascular disease), severity of CAD 
(younger age of CABG necessity [£ 50 years], left 
main stenosis, three vessels disease) and these 
derived from ICC analysis of SMCs proteins (both 
weak and strong expressions of SM-MHC, CALP 
and CK8) were entered into logistic regression 
analysis.
Freedom from CAD progression was estimated 
using Kaplan-Meier method. All statistical analysis 
were carried out using Statistica 9.0 for Windows 
(StatSoft, Inc., Tulsa, OK, USA).
Results
Clinical observation: Late coronary outcome
Eight individuals enrolled to the study protocol 
were discarded from both clinical and angiographic 
analysis of late coronary outcome. Six of them 
died either soon after surgery (due to postcar-
diotomy low cardiac output syndrome [n = 2], 
gastro-intestinal complications [n = 1]) or during 
follow-up for non-cardiac-related causes [n = 3]). 
Other 2 developed perioperative MI (troponin-
-positive with ST segment elevation and evident 
de novo segmental pathologies in left ventricular 
myocardial contractility).
During follow-up period, lasting 45.4 ± 5.7 
months and completed by 100% of the study 
participants, the primary clinical endpoint of the 
study was reached by 38 of them (38/210; 18.1%). 
It confined deterioration of stable angina according 
to CCS classification in 30 and ACSs in 8 cases 
(STEMI [n = 4], NSTEMI [n = 2] and unstable 
angina [n = 2]). Comparison of stable angina sta-
tus according CCS classification before and after 
surgery is presented graphically in Figure 1. Free-
dom from CAD progression estimated by means of 
Kaplan-Meier method was 0.95 ± 0.02, 0.87 ± 0.03 
and 0.83 ± 0.04, respectively for 12-, 24-, 36-month 
follow-up. Forty four individuals reached the pri-
mary angiographic endpoint of the study (Fig. 2), 
including 37 patients with clinical symptoms of 
CAD progression. SVGD development was usually 
accompanied by progression of atherosclerosis in 
the native coronary arteries. Only in 1 case culprit 
lesions in the native vascular bed but not in bypass 
grafts were regarded as reason of marked clinical 
CAD deterioration. 
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ments (n = 60). In 10 (4.6%) cases its expression 
was recognized as positively strong (IRS ≥ 7). 
In the rest of cases, SM-MHC expression was 
accepted as weakly or moderately positive. If preent, 
SM-MHC was localized regularly within the whole 
SMC, except of nucleus territory.
CALP was expressed in all studied SV trans-
plants. In majority of cases (n = 200, 91.3%), its 
cytoplasmic presence within SMCs was regarded 
as moderately or strongly positive. It was not seen 
within tunica adventitia or loose connective tissue 
present in tunica media.
In more than 50% of analyzed SV transplants, 
there were no expression of CK8 (IRS 0–1). Other-
wise, only in 34 cross-sections of SV grafts (15.6%) 
it was assessed as strongly positive in tunica media. 
Similarly to SM-MHC expression, CK8 occupied 
the whole SMCs cytoplasm except of nucleus.
Comparison of patients with and without 
venous graft failure
Generally, SVGD(+) patients at the time of 
surgery were significantly younger as compared 
to SVGD(–) subjects (57.8 ± 8.3 vs. 63.6 ± 8.5, 
p < 0.001). No significant differences in prevalence 
of commonly accepted risk factors for atheroscle-
rosis development (obesity, arterial hypertension, 
diabetes) as well as postoperative medical therapy 
Figure 1. Canadian Cardiovascular Society (CCS) classifi-
cation before and after surgery. Note: CCS classification 
applies only to stable angina patients; *p < 0.05 preop vs. 
4th week and preop vs. late follow-up; preop — pre-
operative.
Figure 2. Final follow-up computed to-
mography angiography of 49-year-old 
man with severe angina deterioration 
(CCS class III at the end of follow-up) 
revealed significant stenosis (arrow) 
in saphenous vein (SV) graft to the 
right coronary artery (A) and proper 
angiographic appearance of left inter-
nal mammary artery (LIMA) implan-
ted to left anterior descending artery 
(LAD) (B). Note almost no expression 
of smooth muscle myosin heavy chain 
(IRS 1) (C) but strong immunoreacti-
vity of cytokeratin 8 (IRS 12) (D) on 
the cross-sections of the harvested SV 
segments; Ao — aorta; Int — SV tunica 
intima; L — SV lumen; LV — left ven-
tricle; Med — SV tunica media; PDA — 
posterior descending artery.
Expression of SMCs proteins
ICC expression of a-SM actin was estimated 
in all the studied SV grafts. Its expression was 
present within SMCs cytoplasm and referred to 
IRS 9 or 12 regardless postoperative clinical course 
of CABG patients (data not shown). Interestingly 
SM-MHC was not expressed in 27.5% of SV seg-
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(statins, acetylsalicylic acid [ASA]) were found 
between groups (Table 3). Statistical analysis of 
SMCs cytoskeletal expression pattern predicting 
development of atherosclerotic plaques in SV grafts 
revealed the risk of critical transplant occlusion is 
higher in CK8-positive (Fig. 3) and CALP-weak 
positive study participants. All the detailed infor-
mation are summarized in Table 3.
Regression analysis
Nine variables (age £ 50 years, gender, previous 
PCI, three vessels disease, SM-MHC IRS ≥ 7, 
weak CALP expression, CALP IRS ≥ 7, no or 
weak CK8 expression and CK8 IRS ≥ 7) reached 
p < 0.2 in the univariate model and were then ana-
lyzed in the multivariate one. That latter one revealed 
a strong expression of CK8 (OR 1.90, 95% CI 1.11– 
–7.76, p = 0.037) and weak of CALP (OR 1.40, 95% 
CI 1.04–6.57, p = 0.042) were the independent risk 
factors for SVGD development. Otherwise, the strong 
expression of both CALP and SM-MHC as well as lack 
of CK8 were associated with low risk for restricting 
lesions development in venous aortocoronary grafts 
and, in consequence, favorable CABG long-term 
outcome. The results of logistic regression model 
to indentify independent risk factors for late SVGD 
development are presented in Table 4.
Discussion
The main purpose of CABG is to bridge over 
lesions compromising adequate flow in the co-
ronary arteries and thus to improve myocardial 
perfusion. Clinically CABG patients usually expe-
rience marked improvement in quality of life, better 
physical performance and relief from angina [17]. 
This effect persists unless development of graft 
disease or rapid progression of atherosclerosis 
in the native coronary arteries [18]. In our study 
it was shown the majority of CABG patients pre-
sented significant improvement in CAD symptom 
control at least 3–4 years after surgery. However, 
a subset of CABG individuals with post-discharge 
CAD deterioration had been growing systematical-
ly by the end of follow-up period (Fig. 1). The last 
follow-up angiographic examination revealed CAD 
symptoms recurrence and progression were asso-
ciated with SVGD. However, it must be stressed 
that 7 patients reached the primary angiographic 
endpoint without any clinical manifestation of CAD 
progression. All of them had diabetes treated with 
insulin for at least 5 years. Thus it is likely that the 
clinical and angiographic endpoints discrepancy 
may have resulted from diabetes-related cardiac 
autonomic neuropathy [19].
Table 3. A comparison of selected clinical data and expression of cytoskeletal smooth muscle cells 
proteins between SVGD(+) and SVGD(–) patients.
SVGD(+); n = 44 SVGD(–); n = 174 P
Age [years] 57.8 ± 8.3 63.6 ± 8.5 < 0.001
Age £ 50 years 18 (40.9%) 22 (12.6%) < 0.001
Age > 70 years 6 (13.6%) 42 (24.1%) 0.092
Obesity (BMI > 30) 20 (45.4%) 72 (41.3%) 0.632
Arterial hypertension 34 (77.3%) 128 (73.6%) 0.609
Diabetes treated with insulin 10 (22.7%) 32 (18.4%) 0.540
Hyperlipidemia 16 (36.3%) 76 (43.7%) 0.378
Peripheral vascular disease 8 (18.2%) 42 (24.1%) 0.379
Postoperative statins 43 (97.7%) 170 (97.7%) 0.998
Postoperative ASA/clopidogrel 44 (100.0%) 174 (100.0%) 1.000
Median SM-MHC IRS score 1 (1–4) 2 (1–4) 0.032
No or weak SM-MHC expression 28 (63.3%) 112 (64.3%) 0.929
Strong SM-MHC expression 0 (0%) 10 (5.7%) 0.001
Median CALP IRS score 6 (2–6) 8 (6–9) < 0.001
Weak CALP expression 12 (27.3%) 6 (3.4%) 0.001
Strong CALP expression 6 (13.6%) 74 (42.5%) < 0.001
Median IRS score 7.5 (4–9) 0 (0–4) < 0.001
No or weak CK8 expression 8 (18.2%) 128 (73.6%) < 0.001
Strong CK8 expression 22 (50.0%) 12 (6.9%) < 0.001
IRS score are presented as medians (25th–75th percentile); ASA — acetylsalicylic acid; BMI — body mass index; CALP — calponin;  
CK8 — cytokeratin 8; IRS — immuno-reactive score; SM-MHC — smooth muscle myosin heavy chain; SVGD — saphenous vein graft disease
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Figure 3. Final follow-up angiographic 
normal appearance of saphenous vein 
(SV) transplant to marginal branch (A) 
in 77-year-old male patient without any 
clinical symptoms of coronary artery 
disease deterioration throughout post-
-discharge follow-up. On the cross-
-sections of the SV segments obtained 
intraoperatively, strong immunorea-
ctivity of both smooth muscle myosin 
heavy chain (IRS 9) (B) and calponin 
(IRS 12) (C) but no expression (IRS 0) 
of cytokeratin 8 (D) were visualized in 
tunica media; Cx — circumflex artery; 
Int — SV tunica intima; L — SV lumen; 
Med — SV tunica media.
Table 4. The results of uni- and multivariate logistic regression analysis.
Variable Univariate Multivariate OR (95% CI)
Age £ 50 years 0.001 0.289 –
Age > 70 years 0.384 – –
Gender 0.059 0.961 –
Obesity 0.843 – –
Unstable angina 0.364 – –
Previous MI 0.874 – –
Previous PCI 0.146 0.239 –
Arterial hypertension 0.484 – –
Diabetes mellitus 0.636 – –
Hyperlipidemia 0.634 – –
Peripheral vascular disease 0.827 – –
Left main disease 0.248 – –
Three vessel disease 0.047 0.181 –
No or weak SM-MHC expression 0.595 – –
SM-MHC IRS ≥ 7 0.027 0.037 0.52 (0.05–0.97)
Weak CALP expression <0.001 0.042 1.40 (1.04–6.57)
CALP IRS ≥ 7 0.001 0.006 0.21 (0.07–0.64)
No or weak CK8 expression < 0.001 0.021 0.11 (0.02–0.72)
CK8 IRS ≥ 7 < 0.001 0.037 1.90 (1.11–7.76)
BMI — body mass index; CALP — calponin; CI — confidential interval; CK8 — cytokeratin 8; IRS — immuno-reactive score; MI — myocardial 
infarction; OR — odds ratio; PCI — percutaneous coronary intervention; PVD — peripheral vascular disease; SM-MHC — smooth muscle 
myosin heavy chain
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Statistical analysis revealed that SVGD(+) 
subjects were markedly younger than SVGD(–). It 
may be related to more aggressive atherosclerosis 
in younger CAD patients [20]. Relatively young age 
was found significantly predictive of angina recur-
rence not only after CABG but also after PCI [21]. 
Moreover, we have shown recently, in the elderly 
CABG individuals both SV wall and tunica media 
were hypotrophic [22]. However, SVGD(+) and 
SVGD(–) patients did not differ to one another with 
respect to prevalence of such factors for atheroma 
formation as obesity, diabetes mellitus, hyperlipi-
demia, arterial hypertension or peripheral vascular 
disease. It could not rule out that aforementioned 
factors would be of importance in longer follow-
-up (e.g. 10–15 years after surgery). Moreover, 
the same postoperative medical management, 
including statins and ASA was applied. Thus it 
is likely that other undisclosed factors may also 
have a potent impact on long-term performance 
of venous aortocoronary bypass grafts.
It was proved previously, a long-term clinical 
and angiographic success of SV as aortocoronary 
bypass graft was determined by the inevitable 
biological process called “arterialization” [23, 24]. 
SMCs and fibroblasts are the main effector cells of 
arterialization, and in the consequence crucial for 
long-term fate of grafts. In our study we evalu-
ated expression of cytoskeletal SMCs proteins 
such as a-SM actin, SM-MHC, CALP and CK8 in 
the SV tunica media. a-SM actin was employed to 
identify SMCs within SV tunica media as it usually 
detected in all stages of SMCs development [10]. In 
all SV specimens a-SM actin positive cells within 
tunica media were found. SM-MHC and CALP are 
usually expressed in well differentiated, mature, 
contractile phenotype SMCs [10, 12]. In our study 
we found SVGD(+) patients had no strong SM- 
-MHC expression and only 6 (14%) cases of them 
presented strong expression of CALP. Contrary to 
them, among SVGD(–) individuals more than 40% 
of medial SMCs manifested strong CALP immu-
nostaining. Another examined cytoskeletal SMCs 
protein, CK8 is not usually detected in normal, well 
differentiated contractile SMCs. It has been found 
previously in both immature, fetal or in synthetic 
SMCs that could migrate from tunica media into 
the neointima [11, 25]. Interestingly, although we 
examined SV segments obtained from the adults 
we detected positive strong expression of CK8 in 
50% (!!!) of SVGD(+) individuals while in much 
less than 10% of SVGD(–) subjects. Additionally, 
aforementioned findings were supported by logistic 
regression model that revealed different expres-
sions of venous medial smooth muscle proteins 
associated with various stages of differentiation 
were of paramount importance for long-term 
CABG outcome. Strong expression of CK8 in 
medial SMCs and weak expression of CALP were 
confirmed to be the independent risk factors for 
unfavorable outcome after CABG with the use of 
SV conduits. Thus degree of SMCs differentiation 
within SV tunica media has impact on their ability 
to respond to various aforementioned biologically 
active chemo-attractant and mitogenic molecules. 
Higher representation of poorly differentiated, 
probably synthetic SMCs is linked to accelerated 
development of culprit lesions in venous aortocoro-
nary bypass grafts. This finding should provoke 
the following question, why in some adult patients 
expression of CK8, fetal cytoskeletal protein, is 
so strong while CALP and SM-MHC markedly 
diminished. It was proved the contractile, mature 
SMCs may undergo dedifferentiation in synthetic 
phenotype under pathological circumstances such 
as ischemia, repetitive injuries (mechanical, in-
flammatory etc.), prolonged exposure to growth 
factors (e.g. VEGF) in the experimental models 
but also in atherosclerotic lesions [26, 27]. This 
phenotypic modulation is usually accompanied by 
a loss of contractile function together with progres-
sively impaired expression of cytoskeletal markers 
of maturity. This process of SMCs change seems 
to be reversible (reversibly synthetic SMCs) but 
if causative factor persists SMCs may become in-
capable of return or return to the contractile state 
is incomplete (irreversibly synthetic cells) [27]. 
Thus, it might be some of CK8 strong positive and 
CALP weak positive SMCs presented irreversibly 
synthetic phenotype that featured high potential to 
biological activity (i.e. proliferation, migration etc.).
Our study supports earlier findings that me-
dial SMCs in SV wall do not represent homoge-
nous population in terms of not only morphology 
(different shapes of both cells and their nuclei) 
but also their biological properties (variations in 
response to potent mitogenic molecules) [10, 28]. 
We have also proved this biological variability had 
significant impact on CABG outcome with the use 
of SV grafts. 
The findings of this study should encourage 
surgeons in cooperation with histologists to work 
out a simple test to identify SV segments with high 
likelihood of the accelerated venous graft disease 
and unfavorable outcome after CABG. Positive 
result of the screening method would disqualify 
SV segment from use and encourage surgeon to 
employ alternative sources of the conduits.
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Conclusions
Strong expression (IRS ≥ 7) of CK8 and weak of 
calponin (IRS 2–3) in tunica media of SV transplants 
may be useful markers in identification of venous 
segments exposed to accelerated atheroma formation 
and, in consequence, venous graft failure. In the fu-
ture, assessment of these proteins expression it will 
enable to select the groups of CABG patients who 
will benefit particularly from SV aortocoronary grafts. 
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